GMAB Quote, Financials, Valuation and Earnings

Galecto has a net margin of 59.7% compared to Genmab AS's net margin of --. Genmab AS's return on equity of 23.85% beat Galecto's return on equity of --.

Genmab AS has a consensus price target of $29.38, signalling upside risk potential of 56.17%. On the other hand Galecto has an analysts' consensus of $8.00 which suggests that it could grow by 244.83%. Given that Galecto has higher upside potential than Genmab AS, analysts believe Galecto is more attractive than Genmab AS.

Genmab AS has a beta of 1.074, which suggesting that the stock is 7.36% more volatile than S&P 500. In comparison Galecto has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Genmab AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Galecto offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genmab AS pays -- of its earnings as a dividend. Galecto pays out -- of its earnings as a dividend.

Genmab AS quarterly revenues are $920.3M, which are larger than Galecto quarterly revenues of --. Genmab AS's net income of $549.4M is higher than Galecto's net income of -$6.7M. Notably, Genmab AS's price-to-earnings ratio is 10.74x while Galecto's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genmab AS is 3.90x versus -- for Galecto. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 59.7% compared to Genmab AS's net margin of 15.24%. Genmab AS's return on equity of 23.85% beat Johnson & Johnson's return on equity of 19.98%.

Genmab AS has a consensus price target of $29.38, signalling upside risk potential of 56.17%. On the other hand Johnson & Johnson has an analysts' consensus of $169.87 which suggests that it could grow by 11.96%. Given that Genmab AS has higher upside potential than Johnson & Johnson, analysts believe Genmab AS is more attractive than Johnson & Johnson.

Genmab AS has a beta of 1.074, which suggesting that the stock is 7.36% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.490, suggesting its less volatile than the S&P 500 by 50.995%.

Genmab AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.27% to investors and pays a quarterly dividend of $1.24 per share. Genmab AS pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Genmab AS quarterly revenues are $920.3M, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. Genmab AS's net income of $549.4M is lower than Johnson & Johnson's net income of $3.4B. Notably, Genmab AS's price-to-earnings ratio is 10.74x while Johnson & Johnson's PE ratio is 26.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genmab AS is 3.90x versus 4.15x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Novo Nordisk AS has a net margin of 59.7% compared to Genmab AS's net margin of 32.95%. Genmab AS's return on equity of 23.85% beat Novo Nordisk AS's return on equity of 86.85%.

Genmab AS has a consensus price target of $29.38, signalling upside risk potential of 56.17%. On the other hand Novo Nordisk AS has an analysts' consensus of $106.93 which suggests that it could grow by 65.19%. Given that Novo Nordisk AS has higher upside potential than Genmab AS, analysts believe Novo Nordisk AS is more attractive than Genmab AS.

Genmab AS has a beta of 1.074, which suggesting that the stock is 7.36% more volatile than S&P 500. In comparison Novo Nordisk AS has a beta of 0.614, suggesting its less volatile than the S&P 500 by 38.645%.

Genmab AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk AS offers a yield of 2.5% to investors and pays a quarterly dividend of $1.10 per share. Genmab AS pays -- of its earnings as a dividend. Novo Nordisk AS pays out 43.71% of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Genmab AS quarterly revenues are $920.3M, which are smaller than Novo Nordisk AS quarterly revenues of $12.2B. Genmab AS's net income of $549.4M is lower than Novo Nordisk AS's net income of $4B. Notably, Genmab AS's price-to-earnings ratio is 10.74x while Novo Nordisk AS's PE ratio is 19.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genmab AS is 3.90x versus 6.86x for Novo Nordisk AS. Usually stocks with elevated PS ratios are considered overvalued.

Zealand Pharma AS has a net margin of 59.7% compared to Genmab AS's net margin of -3213.72%. Genmab AS's return on equity of 23.85% beat Zealand Pharma AS's return on equity of -17.27%.

Genmab AS has a consensus price target of $29.38, signalling upside risk potential of 56.17%. On the other hand Zealand Pharma AS has an analysts' consensus of -- which suggests that it could fall by -64%. Given that Genmab AS has higher upside potential than Zealand Pharma AS, analysts believe Genmab AS is more attractive than Zealand Pharma AS.

Genmab AS has a beta of 1.074, which suggesting that the stock is 7.36% more volatile than S&P 500. In comparison Zealand Pharma AS has a beta of 0.808, suggesting its less volatile than the S&P 500 by 19.219%.

Genmab AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zealand Pharma AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genmab AS pays -- of its earnings as a dividend. Zealand Pharma AS pays out -- of its earnings as a dividend.

Genmab AS quarterly revenues are $920.3M, which are larger than Zealand Pharma AS quarterly revenues of $1.3M. Genmab AS's net income of $549.4M is higher than Zealand Pharma AS's net income of -$41.6M. Notably, Genmab AS's price-to-earnings ratio is 10.74x while Zealand Pharma AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genmab AS is 3.90x versus 457.80x for Zealand Pharma AS. Usually stocks with elevated PS ratios are considered overvalued.